Article
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis.
Oncotarget - 25 Oct 2016
Vincenzi Bruno, Nannini Margherita, Fumagalli Elena, Bronte Giuseppe, Frezza Anna Maria, De Lisi Delia, Spalato Ceruso Mariella, Santini Daniele, Badalamenti Giuseppe, Pantaleo Maria Abbondanza, Russo Antonio, Dei Tos Angelo Paolo, Casali Paolo, Tonini Giuseppe
Abstract excerpt
We retrospectively reviewed data from 123 patients (KIT exon 11 mutated) who received sunitinib or dose-escalated imatinib as second line.All patients progressed on imatinib (400 mg/die) and received a second line treatment with imatinib (800 mg/die) or sunitinib (50 mg/die 4 weeks on/2 off or 37.5 mg/day). Deletion versus other KIT 11 mutation was recorded, correlated with clinical benefits.64% received...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.